Edition:
United Kingdom

Aeglea Bio Therapeutics Inc (AGLE.OQ)

AGLE.OQ on NASDAQ Stock Exchange Global Market

4.87USD
15 Dec 2017
Change (% chg)

$-0.35 (-6.70%)
Prev Close
$5.22
Open
$5.14
Day's High
$5.22
Day's Low
$4.87
Volume
10,647
Avg. Vol
10,474
52-wk High
$8.14
52-wk Low
$2.81

Chart for

About

Aeglea BioTherapeutics, Inc. is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company's product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102,... (more)

Overall

Beta: --
Market Cap(Mil.): $87.77
Shares Outstanding(Mil.): 16.45
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.66 16.44
EPS (TTM): -- -- --
ROI: -- 2.36 10.62
ROE: -- 2.96 14.20

BRIEF-Aeglea Biotherapeutics announces clinical collaboration with Merck

* Aeglea Biotherapeutics announces clinical collaboration with Merck to evaluate the combination of Aeglea’S AEB1102 (pegzilarginase) with Merck's Keytruda® (pembrolizumab) for the treatment of small cell lung cancer

16 Oct 2017

BRIEF-Aeglea BioTherapeutics reports Q2 loss per share $0.47‍​

* Aeglea BioTherapeutics provides corporate update and reports second quarter 2017 financial results

09 Aug 2017

Earnings vs. Estimates